Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Just A Product, Not A Pathway, FDA Says Of Omnitrope Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Sandoz' follow-on human growth hormone does not establish a precedent for follow-on proteins for biologics regulated under the Public Health Service Act.

You may also be interested in...



Advair Competition: Teva’s AirDuo Approved But Not Therapeutically Equivalent

US FDA approves Teva’s fluticasone/salmeterol fixed-dose combination product under the 505(b)(2) NDA route with an asthma indication but no labeling claim for chronic obstructive pulmonary disease.

Congress Will Look To “Hesitant” FDA To Regulate Biosimilars – Former HHS Deputy

Follow-on biologics, and their eventual road to approval, were weighty discussion topics on the opening day of the BIO CEO conference.

Congress Will Look To “Hesitant” FDA To Regulate Biosimilars – Former HHS Deputy

Follow-on biologics, and their eventual road to approval, were weighty discussion topics on the opening day of the BIO CEO conference.

Related Content

Topics

UsernamePublicRestriction

Register

PS064256

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel